WO2010025303A1 - Dosing and monitoring patients on nitrogen-scavenging drugs - Google Patents
Dosing and monitoring patients on nitrogen-scavenging drugs Download PDFInfo
- Publication number
- WO2010025303A1 WO2010025303A1 PCT/US2009/055256 US2009055256W WO2010025303A1 WO 2010025303 A1 WO2010025303 A1 WO 2010025303A1 US 2009055256 W US2009055256 W US 2009055256W WO 2010025303 A1 WO2010025303 A1 WO 2010025303A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hpn
- pba
- patient
- pagn
- dosage
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 174
- 229940079593 drug Drugs 0.000 title claims abstract description 172
- 238000012544 monitoring process Methods 0.000 title claims abstract description 54
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims abstract description 567
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 467
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 claims abstract description 406
- 229910021529 ammonia Inorganic materials 0.000 claims abstract description 283
- 230000002485 urinary effect Effects 0.000 claims abstract description 263
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 234
- 229940002612 prodrug Drugs 0.000 claims abstract description 224
- 239000000651 prodrug Substances 0.000 claims abstract description 224
- 238000000034 method Methods 0.000 claims abstract description 193
- 239000002699 waste material Substances 0.000 claims abstract description 101
- 230000002000 scavenging effect Effects 0.000 claims abstract description 93
- 238000011282 treatment Methods 0.000 claims abstract description 90
- 108010010256 Dietary Proteins Proteins 0.000 claims abstract description 89
- 102000015781 Dietary Proteins Human genes 0.000 claims abstract description 89
- 235000021245 dietary protein Nutrition 0.000 claims abstract description 89
- 230000014759 maintenance of location Effects 0.000 claims abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 38
- 208000020832 chronic kidney disease Diseases 0.000 claims abstract description 31
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims abstract description 30
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims description 558
- ZSDBFLMJVAGKOU-UHFFFAOYSA-N glycerol phenylbutyrate Chemical compound C=1C=CC=CC=1CCCC(=O)OCC(OC(=O)CCCC=1C=CC=CC=1)COC(=O)CCCC1=CC=CC=C1 ZSDBFLMJVAGKOU-UHFFFAOYSA-N 0.000 claims description 496
- 229960002815 glycerol phenylbutyrate Drugs 0.000 claims description 492
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 466
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 claims description 104
- 208000030954 urea cycle disease Diseases 0.000 claims description 104
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 101
- 229950009215 phenylbutanoic acid Drugs 0.000 claims description 96
- 238000006243 chemical reaction Methods 0.000 claims description 74
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 60
- 230000029142 excretion Effects 0.000 claims description 56
- 239000004202 carbamide Substances 0.000 claims description 53
- 210000002700 urine Anatomy 0.000 claims description 44
- 230000000694 effects Effects 0.000 claims description 36
- 208000007386 hepatic encephalopathy Diseases 0.000 claims description 36
- 238000012360 testing method Methods 0.000 claims description 32
- 229940109239 creatinine Drugs 0.000 claims description 30
- 230000007704 transition Effects 0.000 claims description 27
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims description 23
- 230000036765 blood level Effects 0.000 claims description 23
- 229940049953 phenylacetate Drugs 0.000 claims description 23
- 230000015572 biosynthetic process Effects 0.000 claims description 22
- 235000018102 proteins Nutrition 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 238000003786 synthesis reaction Methods 0.000 claims description 21
- 235000005911 diet Nutrition 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 9
- 230000037213 diet Effects 0.000 claims description 8
- 230000000378 dietary effect Effects 0.000 claims description 6
- 238000012423 maintenance Methods 0.000 claims description 4
- 230000021332 multicellular organism growth Effects 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract description 28
- 230000036325 urinary excretion Effects 0.000 abstract description 17
- 238000009825 accumulation Methods 0.000 abstract description 11
- 229960003424 phenylacetic acid Drugs 0.000 description 213
- 239000003279 phenylacetic acid Substances 0.000 description 213
- 239000011734 sodium Substances 0.000 description 128
- 229910052708 sodium Inorganic materials 0.000 description 128
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 127
- 210000002381 plasma Anatomy 0.000 description 69
- 230000036470 plasma concentration Effects 0.000 description 55
- 210000004369 blood Anatomy 0.000 description 42
- 239000008280 blood Substances 0.000 description 42
- 238000003379 elimination reaction Methods 0.000 description 30
- 230000008030 elimination Effects 0.000 description 29
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 description 27
- 229960002232 sodium phenylbutyrate Drugs 0.000 description 26
- 208000019423 liver disease Diseases 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 18
- 238000005259 measurement Methods 0.000 description 18
- 230000003285 pharmacodynamic effect Effects 0.000 description 18
- 229940057372 buphenyl Drugs 0.000 description 16
- 230000001839 systemic circulation Effects 0.000 description 15
- 206010016654 Fibrosis Diseases 0.000 description 14
- 230000007882 cirrhosis Effects 0.000 description 14
- 208000019425 cirrhosis of liver Diseases 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 206010020575 Hyperammonaemia Diseases 0.000 description 12
- 230000009885 systemic effect Effects 0.000 description 11
- -1 e.g. Chemical compound 0.000 description 10
- 230000002596 correlated effect Effects 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 239000002207 metabolite Substances 0.000 description 9
- 235000021075 protein intake Nutrition 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 8
- 230000004143 urea cycle Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000000857 drug effect Effects 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000007726 management method Methods 0.000 description 6
- 239000002547 new drug Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 235000018823 dietary intake Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- UTYVDVLMYQPLQB-UHFFFAOYSA-N phenylacetylglycine Chemical compound OC(=O)CNC(=O)CC1=CC=CC=C1 UTYVDVLMYQPLQB-UHFFFAOYSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 101710191958 Amino-acid acetyltransferase Proteins 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- NZFDAIOXNKSEFX-UHFFFAOYSA-N 2-(4-phenylbutanoylamino)acetic acid Chemical compound OC(=O)CNC(=O)CCCC1=CC=CC=C1 NZFDAIOXNKSEFX-UHFFFAOYSA-N 0.000 description 2
- 229940121848 Ammonia scavenger Drugs 0.000 description 2
- 102000009042 Argininosuccinate Lyase Human genes 0.000 description 2
- 102000053640 Argininosuccinate synthases Human genes 0.000 description 2
- 108700024106 Argininosuccinate synthases Proteins 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000034600 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome Diseases 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 2
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000009894 physiological stress Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000021023 sodium intake Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- PSLCKQYQNVNTQI-BHFSHLQUSA-N (2s)-2-aminobutanedioic acid;(2s)-2-aminopentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O PSLCKQYQNVNTQI-BHFSHLQUSA-N 0.000 description 1
- XKQKXKRCMAJADR-LBPRGKRZSA-N (2s)-5-amino-5-oxo-2-(4-phenylbutanoylamino)pentanoic acid Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CCCC1=CC=CC=C1 XKQKXKRCMAJADR-LBPRGKRZSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 102000006941 Amino Acid Transport System X-AG Human genes 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 108091006151 Glutamate transporters Proteins 0.000 description 1
- 208000034596 Gyrate atrophy of choroid and retina Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- XKQKXKRCMAJADR-UHFFFAOYSA-N Phenylbutyrylglutamine Chemical compound NC(=O)CCC(C(O)=O)NC(=O)CCCC1=CC=CC=C1 XKQKXKRCMAJADR-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- IXDLWFQZQQBARS-UHFFFAOYSA-N butanoyloxymethyl 4-phenylbutanoate Chemical compound CCCC(=O)OCOC(=O)CCCC1=CC=CC=C1 IXDLWFQZQQBARS-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000004802 monitoring treatment efficacy Methods 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 208000014380 ornithine aminotransferase deficiency Diseases 0.000 description 1
- 201000007976 ornithine translocase deficiency Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 150000004072 triols Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- This invention relates to treatment of patients with nitrogen retention states, including urea cycle disorders (UCDs), cirrhosis complicated by hepatic encephalopathy (HE) and chronic renal failure (CRF), using administered compounds that assist in elimination of waste nitrogen from the body.
- the compounds can be orally administered small-molecule drugs, and the invention provides methods for delivering such compounds and selecting suitable dosages for a patient as well as adjusting dosages and monitoring effectiveness of a treatment.
- inherited disorders e.g., UCDs
- acquired disorders e.g.
- Drug dosing is usually based upon measurement of blood levels of the active drug species in conjunction with clinical assessment of treatment response.
- the present invention is based on evidence that for certain prodrugs of phenylacetic acid (PAA), measuring the blood level of the prodrug (e.g. PBA) or of PAA formed from it is unreliable in assessing drug effect: drug levels in the blood do not correlate with efficacy in this case.
- assessment of treatment effect by measuring levels of ammonia in the blood in UCD patients is also potentially unreliable. Individual ammonia level measurements vary several-fold over the course of a day for a given patient, and withdrawing multiple blood samples under carefully controlled conditions over an extended period of time is clinically impractical as a way to monitor a treated patient.
- the variability in blood ammonia levels reflects the fact that ammonia levels in UCD patients are affected by various factors including dietary protein and timing in relation to meals, such that any individual value fails to provide a reliable measure of how much ammonia the drug is mobilizing for elimination; i.e. drug effect.
- the invention demonstrates that prodrugs of phenylbutyric acid (PBA) behave similarly to sodium PBA, in that measuring PBA levels is unreliable for assessing their effectiveness.
- PBA phenylbutyric acid
- This invention provides a novel method for dosing in patients with nitrogen retention states, in particular patients with liver disease and clinical manifestations of hepatic encephalopathy and patients with UCDs. It is particularly applicable to prodrugs that liberate or are metabolized to form phenylacetic acid, i.e., prodrugs of PAA, and those prodrugs that are metabolized to form PBA.
- Hepatic encephalopathy refers to a reversible spectrum of neurologic signs and symptoms which frequently occur in patients with cirrhosis or certain other types of liver disease.
- Urea cycle disorders comprise several inherited deficiencies of enzymes or transporters necessary for the synthesis of urea from ammonia.
- the urea cycle is depicted in Figure Ib, which also illustrates how certain ammonia-scavenging drugs act to assist in elimination of excessive ammonia.
- UCDs include inherited conditions associated with insufficient function of any one of several ammonia-processing enzymes. Individuals born with no meaningful residual urea synthetic capacity typically present in the first few days of life (neonatal presentation). Individuals with residual function typically present later in childhood or even in adulthood, and
- arginase (ARG; EC Number 3.5.3.1; autosomal recessive), (ARG) and
- N-acetyl glutamine synthetase N-acetyl glutamine synthetase
- Ornithine translocase deficiency hyperornithinemia, hyperammonemia, homocitrullinuria or HHH Syndrome
- the common feature of UCDs and similar conditions and hepatic encephalopathy that render them treatable by methods of the invention is an accumulation of excess waste nitrogen in the body, and hyperammonemia.
- CRF is similarly characterized by build-up of excessive waste nitrogen in the blood in the form urea, and the ammonia scavenging drugs described herein are likewise effective to prevent accumulation of excess levels of urea.
- the body's intrinsic capacity for waste nitrogen excretion is greater than the body's waste nitrogen production, so waste nitrogen does not accumulate and ammonia does not build up to harmful levels.
- waste nitrogen builds up in the body of a patient having a nitrogen retention disorder, which usually results in excess ammonia in the blood. This has various toxic effects; drugs that help eliminate the excess ammonia are an important part of an overall management strategy for such disorders.
- dietary intake of protein (a primary source of exogenous waste nitrogen) must be balanced by the patient's ability to eliminate excess ammonia. Dietary protein can be limited, but a healthy diet requires sufficient protein to support normal growth (i.e. in growing children) and repair; thus in addition to controlling dietary protein intake, drugs that assist with elimination of nitrogen are used to reduce ammonia build-up (hyperammonemia).
- the capacity to eliminate excess ammonia in treated patients can be considered the sum of the patient's endogenous capacity for nitrogen elimination (if any) plus the amount of additional nitrogen-elimination capacity that is provided by a nitrogen scavenging drug.
- the methods of the invention use a variety of different drugs that reduce excess waste nitrogen and ammonia by converting it to readily-excreted forms, such as phenylacetyl glutamine (PAGN).
- PAGN phenylacetyl glutamine
- the invention relates to methods for determining or adjusting a dosage of an oral drug that forms PAA in vivo, which is converted into PAGN, which is then excreted in urine and thus helps eliminate excess nitrogen.
- PBA is currently the preferred nitrogen scavenging drug for UCD patients in need of substantial nitrogen elimination capacity.
- Current treatment guidelines recommend 4 times per day dosing with PBA, based on the fact that PBA is absorbed rapidly from the intestine when administered in the form of sodium PBA and exhibits a short half life in the bloodstream (Urea Cycle Disorders Conference Group 'Consensus Statement' 2001).
- Current recommendations for sodium phenylbutyrate dosing in UCD patients indicate that dosage should not exceed 600 mg/kg (for patients weighing up to 20 kg) or in any case 20 grams total per day. Frequent dosing helps minimize the peak levels of ammonia, which can be very harmful, and it minimizes buildup of high concentrations of PAA as well.
- CRF chronic renal failure
- causes e.g. diabetes, hypertension, glomerular disease, etc.
- urea a waste product normally present in the urine
- ESRD end-stage renal disease
- urea levels in the blood are commonly used as one measure of renal function and the need for and frequency of renal replacement therapy such as dialysis.
- PAA prodrugs including PBA and HPN-100 can be used to treat CRF as well as UCDs and HE, and methods for determining and adjusting dosage of these PAA prodrugs and monitoring treatment efficacy are among the inventions disclosed herein.
- prodrugs of PAA which do not contain sodium would be preferred for treatment of treatment of those nitrogen retention states, including CRF as well as cirrhosis and HE, which are also known to be associated with sodium and fluid retention manifested, for example, as ascites and or peripheral edema.
- HPN-100 is one such sodium-free PAA prodrug.
- the invention provides a novel approach for determining and adjusting the schedule and dose of orally administered nitrogen scavenging drugs, including sodium phenylbutyrate and glyceryl tri-[4-phenylbutyrate] (HPN-100), based upon the urinary excretion of the drug metabolite phenylacetylglutamine (PAGN) and/or total urinary nitrogen.
- nitrogen scavenging drugs including sodium phenylbutyrate and glyceryl tri-[4-phenylbutyrate] (HPN-100)
- PAGN drug metabolite phenylacetylglutamine
- Urinary PAGN can be measured in various ways; in some embodiments, as described herein, it is a 24-hour measurement, which means measurement of total urinary PAGN output for a period of 24 hours following the first dose of the day of a nitrogen scavenging drug. In other embodiments, a 12-24 hour urinary PAGN level is used, which is the total amount of urinary PAGN excreted over the time period 12-24 hours after the first dose of the day. As an alternative, as described herein, spot testing of urinary PAGN levels can be used, by normalizing the value as a ratio to urinary creatinine output.
- creatinine output is relatively stable for most subjects, and this has been found to be true even in the UCD, HE, and CRF patients receiving the nitrogen scavenging drugs described herein. Because creatinine output is relatively stable, it can be used to normalize urinary PAGN output levels: from a 'spot test' of a partial sample, the ratio of uPAGN to urinary creatinine can be used to estimate a total daily urinary PAGN output. These values may be used in calculations of dosages or protein intake based on urinary PAGN output as well as for determining initial drug dosage for a patient taking a given amount of protein.
- the invention further provides methods to easily monitor treated patients to determine from urinary PAGN output whether their overall treatment program (diet and medication) is working, and when the patient needs a modified treatment program or adjusted drug dosage.
- These methods comprise monitoring urinary PAGN output, either as a 24 hour output, or as a 12-24 hour total urinary PAGN output, or as an estimated value from a spot test, where the urinary output is normalized to urinary creatinine and converted to an estimated 24-hour (or 12-24 hour) output.
- the method comprises comparing that value for urinary PAGN to a cut-off value that distinguishes patients likely to have normal ammonia levels from patients likely to have high ammonia levels.
- Prodrugs of phenylbutyrate (PBA, the active ingredient in BUPHENYL ® (sodium phenylbutyrate), which is the sodium salt of PBA along with small amounts of inert ingredients), which is itself a prodrug of phenylacetic acid (PAA), are especially subject to the effects described herein.
- PBA phenylbutyrate
- BUPHENYL ® sodium phenylbutyrate
- PAGN is efficiently excreted in urine, carrying away two equivalents of nitrogen per mole of PAA converted to PAGN.
- References herein to sodium phenylbutyrate are understood to include reference to the drug product BUPHENYL ® , and BUPHENYL ® was used for the Examples herein wherever test subjects were treated with sodium phenylbutyrate.
- the sodium PBA dosages used in the Examples generally refer to a dosage of BUPHENYL ® , and the amounts of sodium phenylbutyrate in those Examples should be interpreted accordingly.
- the invention uses prodrugs that can be converted into PAA within the body.
- Sodium phenylbutyrate sodium PBA
- HPN-100 is another such drug: it can be hydrolyzed to release PBA, which in turn can be converted to PAA.
- HPN-100 is a prodrug of PBA, and also a pre -prodrug of PAA.
- Clinical evidence demonstrates that HPN-100 is converted into PAA in the body as expected, and that PAA is then linked to a molecule of glutamine and converted into PAGN, which is eliminated in the urine as predicted. This process can be summarized as follows:
- PAGN is mainly excreted in the subject's urine, and removes two molecules of ammonia per molecule of excreted PAGN.
- Each HPN-100 molecule forms three PAA molecules, so each molecule of HPN-100 can promote excretion of six molecules of ammonia.
- the clinical results suggest that conversion of HPN-100 into PBA and PAA is efficient, in that HPN-100 is generally not detectable in blood, but surprisingly suggest that some PBA derived from HPN-100 is converted to PAGN before the HPN-100 (or PBA, or PAA derived from PBA) enters systemic circulation. As a result, systemic levels of PAA or PBA are not reliably correlated with the efficacy of HPN-100 as an ammonia scavenger.
- the invention uses a prodrug of PBA, including HPN-100 and other esters of phenylbutyrate.
- the PBA prodrug is thus a prodrug of a prodrug, since PBA acts to scavenge ammonia after it is converted to PAA and is thus considered a prodrug of PAA.
- the PBA prodrug is an ester of phenylbutyrate, such as those described below; a preferred PBA prodrug for use in the invention is HPN-100.
- an 'equal molar' or 'equimolar' amount of a second drug is to be used along with or instead of a certain amount of a first drug, the amount of each drug is calculated on a molar basis, and the equimolar amount of the second drug is the amount that produces an equal molar amount of active drug in vivo.
- the amount of prodrug will typically refer to the molar amount of the active species formed from that prodrug.
- That active species is usually PAA for the prodrugs described herein, and the molar amount of a prodrug corresponds to the amount of PAA that would form in the body from that amount of the prodrug, assuming complete conversion into PAA occurs in vivo.
- a molecule of HPN- 100 can be metabolized by ester hydrolysis followed by oxidation to form three molecules of PAA, so a mole of HPN-100 would be considered equimolar to three moles of PAA.
- HPN-100 hydrolyzes to form three molecules of PBA (and one molecule of glycerol)
- an equimolar amount of HPN-100 would be one-third of the molar amount of PBA.
- the present invention can use prodrugs of the formula (I):
- the triol backbone liberated by hydrolysis of the esters is glycerol, a normal constituent of dietary triglyceride which is non-toxic.
- the present invention also utilizes phenylbutyrate and phenylacetate prodrugs of the formula II:
- R is a Ci-Cio alkyl group
- R 4 is
- R can be, for example, ethyl, propyl, isopropyl, n-butyl, and the like.
- the compounds of the invention are esters of the congeners of phenylalkanoic and phenylalkenoic acids having an even number of carbon atoms in the alkanoic acid portion, which include phenylacetic acid esters and those of phenylbutyric acid, etc., which can be converted by efficient beta-oxidation processes to phenylacetic acid in the body. They are thus prodrugs for phenylacetic acid. Where n is 2 or 4, the esters are also prodrugs for phenylbutyric acid.
- the alkylene or alkenylene carboxylate group contains 24 or fewer carbon atoms, so n or m is less than 24. In some embodiments, n and m are 0, 2, 4 or 6, and in some preferred embodiments n or m is 2.
- HPN-100 (Formula III):
- the PAA levels in the subject could be monitored and the dose of the prodrug adjusted until the same plasma level of PAA that was effective with the previous treatment is achieved.
- the current invention is based in part on finding that plasma PAA and PBA levels are not well correlated with the dose of a PBA prodrug administered or with ammonia elimination; for monitoring a dosing level of a PBA prodrug, one should not rely upon these parameters to assess the effectiveness of the prodrug. While not bound by the underlying theory, explanations for this effect (i.e. the inconsistent relationship between ammonia scavenging and PBA and/or PAA blood levels) are provided herein.
- C max maximum plasma concentration
- T max time of maximum plasma concentration
- AUC 24 AUC from time 0 to
- the tolerable amount of dietary protein can be calculated for that patient according to the dosage of the ammonia scavenging drug being administered, or the dosage of the ammonia scavenging drug can be adjusted or calculated to compensate for an estimated protein intake.
- the average nitrogen content of dietary protein is well known, as is the stoichiometry for its conversion into PAGN for excretion.
- the prior art has indicated or assumed that all of the PAA prodrug would be converted into uPAGN.
- improved methods for correlating dietary protein, residual endogenous capacity for waste nitrogen excretion, and drug dosage with urinary PAGN excretion are provided.
- Another embodiment is a method for determining and adjusting the dose of an ammonia scavenging drug to be administered to a patient with liver disease, including hepatic encephalopathy, whereby the starting dose would be based on the amount of dietary protein the patient is consuming, the anticipated conversion of the drug to PAGN, and the patient's residual urea synthetic capacity, if any. While the urea synthetic capacity in patients with liver disease would generally be greater than for patients with UCDs, considerable patient to patient variability would be expected among both groups depending, respectively, on the severity of their liver disease and the severity of their inherited enzymatic defect. Dose adjustments based on the observed urinary excretion of PAGN and total waste nitrogen would adjust for these individual patient characteristics.
- HPN-100 by contrast, which is a glyceryl tri-ester of phenylbutyrate, has been found to be absorbed only 40% as rapidly as sodium PBA, enabling dosing three times daily, such as with meals, or even twice daily, such as morning and evening.
- PK pharmacokinetic
- PD pharmacodynamic
- HPN-100 is administered in two doses per day (BID), and in some embodiments it is administered in three doses per day (TID).
- HPN-100 has more stable and often lower plasma levels of PBA than a patient taking sodium PBA itself.
- systemic exposure to PBA for a subject treated with HPN- 100 was 27% lower than that observed for a subject treated with sodium phenylbutyrate.
- the subjects receiving HPN-100 had PBA exposure, measured as a 24 hour AUC, of 540 ⁇ g-hr/mL, compared to 739 ⁇ g-hr/mL for subjects treated with PBA.
- the amounts of PAA (phenylacetic acid), PBA (phenyl butyric acid), or HPN-100 to be administered to a subject as discussed herein refer to a total daily dosage. Because these compounds are used in relatively large daily amounts, the total daily dosage may be taken in two, three, four, five, or six, or more than six daily doses, and different drugs may be administered on different schedules. Thus the total daily dosage better describes a treatment regimen with one drug for comparison to treatments with related drugs.
- Figure Ia depicts human nitrogen retention states including urea cycle disorders (UCDs), cirrhosis (e.g. accompanied by portal systemic shunting and hepatic encephalopathy (HE), and chronic renal failure (CRF).
- UCDs urea cycle disorders
- cirrhosis e.g. accompanied by portal systemic shunting and hepatic encephalopathy (HE)
- CRF chronic renal failure
- Figure Ib shows waste nitrogen disposal via the urea cycle and by the auxiliary pathway involving PAGN.
- Figure 2 depicts a conventional model to describe pharmacokinetic (PK) behavior of a prodrug, which, in the case of phenylbutyrate, assumes that PBA and PAA must reach the systemic circulation in order to be active; i.e., in order to be converted to PAGN and effect ammonia scavenging.
- PK pharmacokinetic
- Figure 3 depicts an adapted model to describe PK behavior of sodium PBA or other drugs such as HPN-100 that can be converted to PBA and PAA, informed by the observations described herein showing that metabolism of HPN-100 results in lower plasma levels of PAA and PBA while providing equivalent pharmacological effect.
- this model allows for 'pre-systemic' conversion of PBA/PAA to PAGN and explains inconsistent relationship between blood levels of these metabolites and PAGN-mediated excretion of waste nitrogen
- Figure 6 shows that PBA levels fluctuate relatively rapidly after dosing in healthy adults, while PAA and PAGN levels reach a fairly stable steady state after a few days of treatment with sodium phenylbutyrate.
- Figure 9 shows plasma ammonia levels [time-normalized area under the curve, or TN- AUC or Area under the curve (AUC)] during the day and night for 10 UCD patients treated for seven days with sodium PBA, or with an equimolar dosage of HPN-100, and illustrates that HPN- 100 provided better control of ammonia levels than PBA: both the AUC (area under the curve), which is an index of total ammonia exposure, and Cmax, which measures the peak concentration of ammonia, were lower in subjects receiving HPN-100 than in subjects receiving an equimolar dosage of PBA.
- AUC area under the curve
- Cmax which measures the peak concentration of ammonia
- Figure 10 shows that HPN-100 did a better job than PBA of managing plasma levels of ammonia overnight.
- Figure 11 demonstrates that in patients whose ammonia levels were well controlled on sodium PBA, HPN-100 maintained control. By contrast, patients whose ammonia levels were elevated despite treatment with sodium PBA exhibited the greatest benefit in terms of improved ammonia control from HPN-100.
- Figure 12 summarizes the data from Figure 11 and provides a statistical comparison of ammonia levels for patients on sodium PBA and those on HPN-100. It also shows the normal range for each set of patients.
- Figure 13 depicts the strong negative correlation between urinary PAGN output and blood ammonia, measured over 24 hours and expressed as time-normalized area under the curve, in patients with urea cycle disorders.
- Figure 14 depicts the effect on blood urea of administered sodium benzoate to a patient with chronic renal failure.
- the invention is reduced to practice in determining the dose, dosing schedule and dose adjustments necessary for treatment of nitrogen retention states including urea cycle disorders and liver disease complicated by hepatic encephalopathy.
- the starting dose and schedule for administration of an ammonia scavenging drug would be based upon the theoretical considerations including the estimated percentage conversion of the drug to PAGN, the waste nitrogen resulting from the patient' s dietary protein, and the percentage of drug converted to and excreted as PAGN.
- further dose adjustments would then be made if necessary, based upon the actual measurement of urinary PAGN output, or a well-correlated parameter like total urinary ammonia or the ratio of PAGN to creatinine.
- PBA plasma levels of PBA do not correlate well with administered dosages of HPN-100 or with the effectiveness of a dose of HPN-100 or sodium PBA.
- sodium PBA is the acid form of phenylbutyrate, which is the common name for the drug BUPHENYL ® , and is typically administered as BUPHENYL ® , which is a sodium salt of PBA.
- PBA is administered as the sodium salt, in the form of the drug BUPHENYL ® .
- the dosage of a phenylbutyrate prodrug could be calculated according to the theoretically formed amount of PAA, which should be the same amount as what would be calculated from the PBA dosage, since one molecule of PBA is expected to produce one molecule of PAA.
- the molecular weight of sodium PBA, the registered drug form of PBA (the sodium salt of PBA), is 186; the molecular weight of HPN-100 is 530, and of course HPN-100 provides three equivalents of PBA per molecule, so only one-third as many moles of HPN-100 would be needed to replace a molar quantity of either PBA or PAA.
- each gram of sodium PBA could be replaced by 0.95 grams of HPN-100; and since HPN-100 is a liquid having a density of 1.1 g/mL, each gram of sodium PBA would be replaced by 0.87 mL of HPN- 100, assuming HPN-100 is used as an undiluted liquid. This can be used to select a starting dosage of HPN-100 for patients being transitioned from sodium PBA to HPN-100.
- a starting dose of HPN-100 in a patient not already taking BUPHENYL ® sodium phenylbutyrate
- BUPHENYL ® sodium phenylbutyrate
- the physician could measure plasma levels of either PBA or PAA in a subject receiving an effective amount of PBA, and determine a dosage of a PBA prodrug by administering enough of the prodrug to produce the same plasma levels of PBA or PAA. The physician could then monitor the amount of either PBA or PAA in the blood to ensure that the appropriate amount of active drug was being produced in the body. It might be expected that a prodrug of phenylbutyrate would provide a slightly lower blood plasma concentration of PAA or PBA than phenylbutyrate, and thus a lower nitrogen-scavenging effect, since conversion of the prodrug to the active drug might be less than 100% efficient.
- HPN-100 is absorbed only about 40% as rapidly as PBA when dosed orally.
- HPN-100 provides a slow-release delivery effect, even though it appears to metabolize to PBA rapidly once absorbed.
- This provides greatly enhanced flexibility in dosing and explains why HPN-100 can be dosed, e.g., three times per day or even twice per day to provide stable ammonia levels that require four or more doses of PBA to achieve.
- This slower release in conjunction with pharmacokinetic and anatomic considerations as depicted in figures 3 and 5, respectively, explain the greater conversion of PBA to PAA/PAGN following administration in the form of HPN-100 as compared with sodium PBA.
- Urinary PAGN has also been shown to be inversely correlated with levels of waste nitrogen, e.g. ammonia, in the blood, thus efficacy of HPN-100 can be evaluated by measuring urinary PAGN. This is particularly valuable because it is very difficult to rely on monitoring of ammonia levels for routine patient maintenance, and surprisingly, none of the other parameters associated with HPN-100 treatment, such as plasma levels of PAA or PBA or PAGN or HPN-100, correlated with ammonia levels well enough to be useful for guiding therapy.
- the invention thus provides a method to determine an effective dosage of a nitrogen scavenging drug, particularly HPN-100, for a patient in need of treatment for a nitrogen retention disorder.
- the patient may be one having a UCD or similar condition, HE, or CRF, for example.
- the method comprises monitoring the effect of an initial dosage of the drug on a subject by determining the subject's urinary PAGN output. While plasma ammonia levels can also be tested, particularly for a treatment na ⁇ ve patient, it is demonstrated herein that the PAGN level can be used much more conveniently for out-patient monitoring, for example, and correlates well with effectiveness of the drug dosage.
- the method further comprises determining from the initial dosage whether a dose adjustment is needed. This can be based on comparing the subject's urinary PAGN output to the subject's daily protein intake, to ascertain whether the expected amount of waste nitrogen is being excreted. Methods for calculating how much nitrogen excretion is needed are known in the art — see Brusilow, et al. Alternatively, as described below, a target level of urinary PAGN can be determined for the subject's population, and the subject's uPAGN can be compared to that target value.
- a cut-off level of about 10 g uPAGN per day distinguishes those who achieve normal plasma ammonia levels (ones having 1Og or higher daily uPAGN output) from those having ammonia levels above normal.
- the subjects for these methods can be patients having HE, CRF, or UCD conditions and needing treatment with a nitrogen scavenging drug.
- uPAGN levels can be determined either as total urinary PAGN over a 24 hour period following the first dose of HPN-100 in a day, or as the 12-24 hour uPAGN output, measured for the period 12-24 hours after the first dose of HPN-100 of the day.
- urinary PAGN output indicates an adjustment is needed
- an adjusted dosage can be determined from the urinary PAGN output in view of the information herein, which demonstrates that a daily dosage of HPN-100 or PBA is converted to a 24-hour urinary PAGN output that corresponds to about 54% of the administered dosage of the drug. If the subject's urinary PAGN output indicates a need to increase or decrease drug dosage, an adjusted dosage can be determined as the amount of additional drug needed to produce the desired uPAGN level, in view of the conversion efficiency of about 54%.
- the desired uPAGN level would be that corresponding to the amount of waste nitrogen to be removed, as calculated from the subject's daily protein intake, or as the difference between the observed uPAGN level and a target uPAGN level for the subject's population as discussed further below.
- the subject's daily protein intake can also be adjusted, if appropriate, for the subject's residual urea synthesis capacity, if any. In many UCD subjects having inborn severe enzyme function deficiencies in the urea cycle or transporter enzymes mentioned above, minimal residual urea synthesis capacity is likely to be present, and no adjustment may be needed. [0077] Plasma levels of ammonia are difficult to measure — a blood sample is needed and must receive special handling to ensure accurate measurement.
- urinary PAGN provides such a measure: it uses the far more practical collection of urine rather than blood samples, and measures a parameter that does not require particularly careful sample storage and handling. Moreover, the measured urinary PAGN level correlates well with ammonia control, while being less prone to fluctuations caused by timing of the sample collection.
- the invention provides a method to determine a dosage of a PAA prodrug for a patient having an ammonia retention disorder, comprising: a) determining the patient's dietary protein intake; b) determining the patient's residual urea synthesis capacity, if any; c) estimating from a) and b) the amount of excess waste nitrogen the patient needs to excrete to remove the waste nitrogen associated with the dietary protein intake that is not excreted as urea; and d) determining an amount of the PAA prodrug needed to eliminate the estimated amount of excess waste nitrogen as urinary PAGN, wherein the amount of PAA prodrug needed is determined based on a conversion factor whereby about 40% to about 70% of the PAA prodrug is converted into urinary PAGN.
- the PAA prodrug can be HPN-100 or PBA in some embodiments. In some embodiments, the conversion factor is about 54%.
- the subject (patient) for these methods can be one having a UCD, HE, or CRF and needing treatment with a nitrogen scavenging drug.
- the patient's urinary PAGN output can be measured as a 24 hour, or a 12-24 hour total output, or it can be estimated from the ratio of PAGN to creatinine in a spot sample of the subject's urine.
- ammonia levels in blood measured as time normalized area under the curve (TN-AUC) exceeded 30 ⁇ mol/L in 7 of 9 patients whose 24-hour urinary PAGN output was under 10 g; while ammonia levels were under 30 ⁇ mol/L in 7 of 9 subjects whose 24-hour urinary PAGN output exceeded 10 g.
- the measured cut-off level in this patient population was 10 g per day, different populations are expected to exhibit different cut-off values; however, based on the surprising observation that a single easily-measured parameter readily predicts whether adequate ammonia control is achieved, determining the correct cut-off value for a particular patient population taking HPN-100 or PBA for ammonia scavenging can be done without undue experimentation. It is only necessary to measure urinary PAGN output for subjects in the population of interest, and assess their ammonia levels, then correlate the ammonia control with urinary PAGN to determine the cutoff value for that population. For a different population, the cut-off level may be about 5g, 6g, 7 g, 8g, 9g, 1Og, Hg, 12g, 13g, 14g, or 15g of urinary PAGN per day.
- the invention provides a method to identify a subject in need of close monitoring, or a need to modify a treatment plan for a subject, where the subject is a person treated with an ammonia scavenging drug, particularly HPN-100 or PBA.
- the method comprises comparing the 24-hour urinary PAGN output for the subject to a cut-off value for the population in which the subject fits. Routine experimentation enables identifying the level of urinary PAGN that correlates with successful ammonia control in the patient's population, as a cut-off level that can be used to distinguish subjects likely to achieve normal ammonia levels from those unlikely to achieve normal ammonia levels, or to identify subjects who need a modified ammonia control treatment program.
- a cut-off level of urinary PAGN output of approximately 10 g per day distinguishes adult UCD patients into groups who generally had normal ammonia levels (those producing over 1O g urinary PAGN per day) and those who failed to achieve normal ammonia levels (those producing less than 10 g urinary PAGN per day).
- the method can also comprise testing a subject by determining the subject's 24-hour urinary PAGN output, and classifying the subject as one likely to have acceptable ammonia control on a current treatment program (normal ammonia levels) based on a urinary PAGN level above the cutoff, or as one likely to have insufficient ammonia control (excessive ammonia levels) on a current treatment program, based on having a urinary PAGN output below the cutoff.
- Subjects having a urinary PAGN output below the cut-off would be recommended to undergo further testing, and possibly an adjusted treatment regimen involving lower protein intake or increased dosage of an ammonia scavenging drug such as HPN-100 would be needed.
- the method can also comprise determining an adjusted dosage of the ammonia scavenging drug for a subject whose urinary output is less than the cut-off level. Determining the cut-off for a given population is a matter of routine experimentation in view of the surprising observation herein showing that this parameter, urinary PAGN, can serve that function. If the drug is HPN-100 or PBA, the conversion efficiency factor of about 54% of administered drug being excreted as urinary PAGN can be used to determine how much additional drug to administer, subject to the limitations on recommended daily dosing of the drug for that subject.
- HPN-100 has little to no effect on urinary creatinine output, and that urinary creatinine levels were about the same for subjects on BUPHENYL® and HPN- 100.
- the average total 24-hour creatinine excretion for a subject receiving PBA was 1.08 (0.43) grams, and for a subject receiving HPN-100, it was 1.03 (0.38) grams.
- daily urinary creatinine outputs in healthy adults and patients with nitrogen retention states are typically rather stable, either measuring PAGN output in urine over time, or measuring the ratio of the concentrations of PAGN to creatinine, which can be conveniently done in spot testing, provides a way to monitor HPN-100's effectiveness.
- the invention thus provides a method to assess the effectiveness of a treatment with HPN-100, comprising determining the ratio of PAGN to creatinine in a 'spot urine' test.
- Clinical studies show that urinary excretion of PAGN, and the ratio of PAGN to creatinine in urine, correlate well with blood ammonia levels: an increase of PAGN or of the PAGN / creatinine ratio correlates with decreasing plasma ammonia levels.
- HPN-100 treated patients are monitored by measuring urinary PAGN output, or by measuring the ratio of PAGN to creatinine in spot urine testing. The ratio from spot testing can be used to estimate a 24-hour uPAGN output level for the subject or a 12-24 hour uPAGN output level.
- urinary PAGN specifically measures the waste nitrogen clearance provided by the scavenging agent, while many other factors affecting ammonia levels may cause ammonia control to be misleading with regard to the actual effect of the nitrogen scavenging drug.
- urinary PAGN only measurements based on urinary PAGN are both convenient and reliable as a direct measurement of the nitrogen scavenging drug's effect.
- the invention provides a method to monitor the effectiveness of treatment of a UCD patient with HPN-100, where monitoring consists essentially of monitoring the patient's urinary PAGN excretion.
- Urinary PAGN levels comparable to those achieved with a previous PBA dosing regimen would be considered evidence that the HPN-100 treatment was equally effective as the PBA treatment it replaced.
- a plasma ammonia level of less than about 40 ⁇ mol/L, or of not greater than 35 ⁇ mol/L would indicate the treatment was effective; however, the method can be practiced without measuring plasma ammonia levels, and in some embodiments, ammonia levels are not used in the determination of efficacy, or they are not used in adjusting a treatment plan, dosage, or protein intake level.
- the invention provides a utilization efficiency factor for HPN-100 or for sodium PBA of about 40% to about 70%, with an average value of about 54%, which can be used to more accurately determine an initial starting dose of either drug and/or correlate dietary protein intake with projected urinary PAGN.
- the invention provides a method for transitioning a patient from phenylbutyrate to HPN-100 or other esters or prodrugs of phenylbutyrate.
- the method involves administering an initial dosage of the prodrug that is selected based on the patient' s current dosage of phenylbutyrate. For example, the amount of HPN-100 needed to provide an equal molar amount of PBA would be calculated (an equimolar amount), and this equimolar amount would be administered to the patient.
- Urinary excretion of PAGN or plasma ammonia levels would be monitored, and the dosage of HPN would be increased or decreased as needed to establish a level of PAGN excretion that is about the same as that provided by a previously used effective amount of phenylbutyrate or another nitrogen scavenging drug.
- a subject being transitioned from PAA or another PAA prodrug onto HPN-100 using this method would be tested for urinary PAGN output prior to the transition and afterwards, and the dosage of HPN-100 would be adjusted as needed to match the urinary PAGN output from this patient when treated with the previous PAA drug or prodrug, assuming the previous PAA prodrug treatment was considered effective.
- the transition from phenylbutyrate might be undertaken in more than a single step and urinary excretion of PAGN and total nitrogen would allow monitoring of ammonia scavenging during the transition.
- a patient taking an initial dosage of phenylbutyrate is transitioned from phenylbutyrate to a prodrug of phenylbutyrate in steps.
- the methods can use two, three, four, five, or more than five steps. At each step, a fraction of the initial dosage of phenylbutyrate corresponding to the number of steps used for the transition is replaced by an appropriate amount of HPN-100 or other prodrug of phenylbutyrate.
- the appropriate amount for each step can be approximately an amount sufficient to provide an equal molar amount of PBA if it is assumed that the prodrug is quantitatively converted into PBA.
- BUPHENYL ® sodium phenylbutyrate
- HPN-100 or prodrug
- HPN-100 can then be adjusted to produce about the same amount of ammonia excretion in the form of excreted PAGN that was achieved by the initial dosage of phenylbutyrate, if the patient was well controlled.
- a physician who is switching a patient from PBA to HPN-100 or another ester of phenylbutyrate should be aware that an effective amount of HPN-100 does not necessarily produce a PAA or PBA level that is as high as those seen when sodium phenylbutyrate is administered. It is reported that PAA exhibits some toxicity at high plasma concentrations. Thibault, et al., Cancer Research, 54(7): 1690-94 (1994) and Cancer, 75(12):2932-38 (1005). Given this, and given the unique properties of HPN-100 described above, it is particularly important that a physician not use plasma levels of PAA or PBA to measure the efficacy of HPN-100. If one administers HPN-100 in amounts sufficient to match the plasma PBA or PAA levels provided by administering phenylbutyrate, for example, the dose of HPN-100 may be unnecessarily high.
- the treatment-na ⁇ ve patient is one not presently receiving an ammonia-scavenging drug treatment to manage nitrogen levels. While there are recommended dosage levels for the nitrogen scavenging drugs in many cases, the right dosage for a na ⁇ ve patient may be lower than those ranges, for example, and, less commonly, it may be above an equimolar amount when compared to the dosages recommended for sodium PBA.
- the initial dosage of PAA or a PAA prodrug can be calculated by methods known in the art once a patient' s dietary intake of protein is known, and assuming the patient has a relatively normal liver function.
- HPN-100 utilization efficiency is between about 40% and 70% in various individual patients (as disclosed herein, it has been found that about 40-70% of HPN-100 is converted into urinary PAGN in the tested UCD patients, with an average value of 54%), which is consistent with clinical observations to date, and the average value of about 54% can be used to further refine the relationship between dietary protein intake and HPN-100 dosing levels for a given subject. With this refinement, each gram of HPN-100 would assist with removal of waste nitrogen for about 1 gram ( ⁇ 1.3 grams) of dietary protein. This factor can be used to calculate a suitable dosage of HPN-100 if dietary protein intake is known or controlled, and it can be used to calculate a tolerable dietary protein intake for subject receiving a set dosage of HPN- 100.
- This method can also be used to establish a recommended daily dietary protein intake for a patient, by determining the patient's endogenous nitrogen elimination capacity, calculating an amount of dietary protein that this endogenous capacity permits the patient to process without assistance from a nitrogen scavenging drug, and adding to the amount of dietary protein the patient can process on his/her own an amount of protein that the patient would be able to process when using a particular dosage of PBA or a PBA prodrug like HPN-100.
- HPN-100 as an example, a daily dosage of about 18 grams of HPN-100, utilized at an estimated efficiency of 54%, would enable the treated patient to eliminate waste nitrogen corresponding to about 25 g of dietary protein.
- the invention provides a method to establish a suitable dietary protein level for a patient having a urea cycle disorder or HE, by adding this amount of protein to the amount the patient's endogenous nitrogen elimination capacity can handle.
- PAGN excretion which accounts for some of the total waste nitrogen excreted when PAA or a PAA prodrug is working.
- the total waste nitrogen excreted minus the amount of PAGN excreted represents the patient's endogenous capacity for excreting nitrogen wastes via the urea cycle or other mechanisms, and is helpful in determining how much protein intake the patient can manage at a given drug dosage, and also for understanding whether the patient requires extremely close monitoring.
- the endogenous capacity to excrete nitrogen wastes will be very patient-specific in some cases, while some patients may be known based on their condition or history to have little or no residual endogenous capacity to eliminate waste nitrogen.
- Dosage of HPN-100 can then be established by determining the subject's endogenous capacity to eliminate waste nitrogen; subtracting the amount of dietary protein corresponding to the subject's endogenous nitrogen elimination capacity; and providing a dosage of HPN-100 sufficient to permit the subject to handle the balance of waste nitrogen, based on the subject's dietary protein intake.
- the amount of urinary PAGN expected from the dosage of HPN-100 can be determined from the average conversion (54%), and this can be used to determine how much urinary PAGN to expect, and the dosage can be adjusted if necessary based on monitoring urinary PAGN output.
- the plasma or blood level of ammonia is optionally also determined, at least periodically if not on an ongoing basis, in addition to measuring urinary PAGN, to assess the effectiveness of the overall drug and dietary regimen for a particular patient. If the ammonia control is inadequate, the dosage of the nitrogen scavenging drug may need to be increased if that can be done, or the patient's dietary protein intake can be decreased if that is feasible.
- the dosage of HPN-100 may be limited to dosages that do not exceed recommended dosing levels for phenylbutyrate, adjusting for the fact that each mole of HPN-100 can produces three moles of phenylbutyrate.
- the label for the use of sodium PBA for the chronic treatment of UCDs recommends a daily dosage not to exceed 20 g; a daily dosage in a range of 9.9-13.0 g/m set according to the subject's size for subjects over 20 kg in weight; and a dosage within a range of 450-600 mg/kg for subjects weighing less than or equal to 20 kg is indicated.
- a dosage range of about 390 to 520 ⁇ L/kg per day of HPN-100 would be appropriate, based on the use of an equimolar amount compared to the recommended doses of HPN-100.
- HPN-100 would produce adverse effects at a rate in excess of that from an equimolar amount of sodium PBA, so the daily recommended upper limit of 20 g per day of sodium PBA suggests that a daily dose limit of HPN-100 based on the recommendations for sodium PBA would correspond to an equimolar amount of HPN-100, or about 19 g or 17.4 mL.
- the invention provides a method to monitor the effectiveness of a treatment of a UCD patient with HPN-100, where monitoring consists of, or consists essentially of, monitoring the patient's urinary PAGN excretion and/or plasma ammonia levels.
- Urinary PAGN levels comparable to those achieved with a previous PBA dosing regimen would be considered evidence that the HPN-100 treatment was equally effective as the PBA treatment it replaced.
- a plasma ammonia level that was normal, e.g., a level of less than about 40 ⁇ mol/L, or of not greater than 35 ⁇ mol/L, or less than about 30 ⁇ mol/L, would indicate the treatment was effective.
- HPN-100 exhibits no indications of toxicity at equimolar doses when compared to the approved PBA dosage of 20 g / day and a dose 2-3 times the equivalent of 20 grams of PBA is unlikely to produce PAA blood levels leading to AEs.
- tolerability of taking HPN-100 is much higher than for PBA and a linear relationship has been observed between HPN-100 dose and PAGN output up to doses of 17.4 mL.
- HPN-100 doses well above the approved PBA dosage are expected to be beneficial; for example, in UCD patients who exhibit recurrent hyperammonemia even on maximal doses of sodium PBA, in UCD patients who need increased dietary protein to support body requirement, or in patients with other nitrogen retaining states.
- the invention provides methods to treat a subject having HE or UCD, with a dosage of HPN-100 that corresponds to between 100 and 300% of the equimolar amount of the recommended highest dose of PBA.
- the suitable dosage will be between about 120% and 180% of the highest recommended dose of PBA; in other embodiments it will be between 120-140% or from 140-160% or from 160-180% of the equimolar amount of the recommended highest dosage of PBA.
- the daily dosage of HPN-100 could be as much as 57 g, or up to about 38 g, or up to about 33 g, or up to about 30g, or up to about 25g.
- the invention provides a method to identify the starting dose or dose range and to individually adjust the dose or dose range of a nitrogen scavenging drug comprising PAA or a PAA prodrug (including HPN-100) used for the management of a treatment- na ⁇ ve patient, which method comprises the steps of: a) administering an initial dosage of the drug estimated according to the patient' s dietary protein load, taking into account the expected percentage conversion to PAGN b) measuring the amount of total waste nitrogen excreted following administration of the nitrogen scavenging drug comprising PAA or a PAA prodrug; c) measuring blood ammonia to determine if the increase in urinary excretion of total waste nitrogen is sufficient to control blood ammonia levels; and d) adjusting the initial dosage to provide an adjusted dosage of the nitrogen scavenging drug comprising PAA or a PAA prodrug based upon ammonia control, dietary protein, and the amount of total waste nitrogen excreted by the patient, or the amount of waste PA
- the method also includes determining the subject's endogenous nitrogen eliminating capacity (residual urea synthesis capacity) to further help determine an initial dose of HPN-100.
- the initial dosage of the HPN-100 for a treatment na ⁇ ve patient can be calculated as the amount of waste nitrogen that needs to be eliminated based on the patient's dietary protein intake. This amount can be reduced by an amount equivalent to the waste nitrogen the patient can eliminate using the patient's endogenous waste nitrogen elimination capacity, which can be measured as described herein.
- the suitable starting dose of HPN-100 can be calculated by estimating dietary protein intake that needs to be managed via the nitrogen scavenging drug, and providing a dose of drug amounting to about 1 g of HPN-100 per 1-2 grams of dietary protein in excess of the amount the patient's endogenous nitrogen elimination capacity can handle, taking into account the expected percentage conversion of the administered PBA to urinary PAGN.
- the method optionally further includes assessing urinary PAGN output to see if it accounts for the expected amount of waste nitrogen, and optionally may include measuring plasma levels of ammonia in the subject to ensure that an acceptable level of ammonia has been achieved. Checking the patient's plasma ammonia levels provides a measure of the effectiveness of the overall treatment program, including diet and drug dosing.
- HPN-100 can be administered in two doses per day, while PBA typically is administered in four doses per day. This is likely associated with the slow- release characteristics of HPN-100 described herein, and is expected to improve quality of life and compliance with the treatment program for subjects receiving HPN-100 rather than PBA.
- plasma levels of ammonia are acceptable when they are at or below a level considered normal for the subject, and commonly this would mean plasma ammonia level is below about 40 ⁇ mol/L.
- the upper limit of normal for the subjects was between 26 and 35 ⁇ mol/L, (e.g., in some of the tests described herein the site average for normal ammonia levels was about 30 ⁇ mol/L), and it is recognized in the art that a normal ammonia level will vary depending upon exactly how it is measured; thus as used to describe ammonia levels herein, 'about' means the value is approximate, and typically is within ⁇ 10% of the stated numeric value, and 'normal' is determined according to the particular testing methods.
- the invention provides a method to identify a suitable starting dose or dose range for a UCD or HE patient and to individually adjust the dose or dose range of a new nitrogen scavenging drug used for the management of a patient already treated with a previous nitrogen scavenging drug, which method comprises the steps of: a) administering an initial dosage of the new nitrogen scavenging drug (which can be estimated according to the patient's dietary protein load and/or the dose of the new drug expected to yield the same amount of urinary PAGN excretion as a previously used nitrogen scavenging drug); b) measuring the amount of total waste nitrogen and/or of PAGN excreted following administration of the new drug; c) optionally measuring blood ammonia to determine if the initial dosage is sufficient to control blood ammonia levels, or to establish a suitable average ammonia level; and d) adjusting the initial dosage of the new drug as needed to provide an adjusted dosage based upon ammonia control, dietary protein, and the amount of total waste nitrogen
- the treating physician may rely, wholly or in part, upon the previous treatment to set a dosage for a new PAA prodrug, or a PBA prodrug, to be administered to the same patient. If the previous drug was reasonably effective for managing the patient's condition, the physician may set the dosage for a new PAA or PBA prodrug by reference to the previous one, so that the new drug is administered at a dosage that provides the same dosage of PAA to the patient, assuming complete conversion of each prodrug into PAA.
- PAGN excreted in addition to total waste nitrogen excreted.
- the total waste nitrogen excreted minus the amount of PAGN excreted represents the patient's endogenous capacity for excreting nitrogen wastes via urea cycle or other mechanisms, and is helpful in determining how much protein intake the patient can manage at a given drug dosage, and also for understanding whether the patient requires extremely close monitoring.
- the endogenous capacity to excrete nitrogen wastes will be very patient- specific.
- the invention provides a method to identify the amount of dietary protein that could be safely ingested by a subject with a nitrogen accumulation disorder, including hepatic encephalopathy and UCD, where the patient is taking an ammonia-scavenging drug that comprises PAA or a PAA prodrug, which method comprises the steps of: a) measuring the amount of total waste nitrogen excreted following administration of the drug,
- the methods of the invention include administering a prodrug as described herein to a subject at a dosage that provides comparable ammonia level control to that achieved by PBA, but with significantly lower exposure of the subject to systemic PBA.
- the subject experiences pharmacokinetic parameters for PBA that demonstrate lower exposure to PBA, including a lower AUC and Cmax for PBA, while maintaining a plasma ammonia level comparable to or better than that provided by treatment with a dosage of PBA within the normal dosing range.
- HPN-100 and PBA were administered to UCD patients at equimolar dosages, the patient receiving HPN-100 had overall lower plasma ammonia levels, and also lower PBA exposure:
- a method to determine an effective dosage of HPN-100 for a patient in need of treatment for a nitrogen retention disorder which comprises monitoring the effect of an initial dosage of HPN-100, wherein monitoring the effect of the initial dosage of HPN-100 consists essentially of determining the patient's urinary phenylacetyl glutamine (PAGN) output; and determining from the patient's urinary PAGN output whether and/or how to adjust the initial dosage of HPN-100 to provide a desired ammonia scavenging effect.
- PAGN urinary phenylacetyl glutamine
- the patient's urinary PAGN output is the patient' s total urinary PAGN for 24 hours following the first dose of HPN-100 of the day, or the patient's total urinary PAGN for the period 12-24 hours following the first dose of HPN-100 of the day.
- the upper curve represents PBA levels; the intermediate one represents PAA levels; and the lowest of the three sets of lines represents PAGN levels.
- the three lowest curves at the 10-15 hour time span are all for PBA; and the highest three curves at 15-25 hours represent PAGN levels. PAA levels were not determined after approximately 12 hours, and were generally close to the PAGN curves up to that time.
- PK blood samples were taken pre-dose, at 15 and 30 minutes post-dose, and at 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose on days 1, 8, and 15, and at 48 hours after dosing on days 1 and 15.
- blood samples were taken pre-morning dose and at 2 hours post- morning dose.
- Urine was collected 0-4, 4-8, 8-12, and 12-24 hours post-dose on days 1, 8, and 15, and at 24-48 hours post-dose on days 1 and 15.
- HPN-100 was metabolized via the predominant pathway in all subject groups, and the alternative HPN-100 metabolites PAG (phenylacetyl glycine), PBG (phenylbutyryl glycine), and PBGN (phenylbutyryl glutamine) were below the limit of quantification in all plasma samples.
- PAG phenylacetyl glycine
- PBG phenylbutyryl glycine
- PBGN phenylbutyryl glutamine
- Child-Pugh B 1.35 0.83-2.21
- Child-Pugh C 1.50 0.92-2.45
- AUCo_ t area under the plasma concentration curve from time 0 to the last measurable concentration; CI, confidence interval; C max , maximum observed plasma concentration; PAA, phenylacetic acid; PBA, phenylbutyric acid.
- HPN-100 The clinical efficacy of HPN-100 is dependent on its ammonia scavenging capabilities, through conjugation of glutamine with PAA to form PAGN.
- PAGN was the major metabolite excreted: 42-49% of the HPN-100 dose administered was excreted as PAGN on day 1, 25-45% on day 8, and 58-85% on day 15.
- Very low amounts of PBA and PAA were excreted in the urine ( ⁇ 0.05% of the total HPN-100 dose). There were no significant differences in the amount of PAGN excreted between any of the Child-Pugh groups and the healthy volunteers.
- Urinary PAGN excretion is also an indication of the ammonia-scavenging capacity of HPN-100, as 2 moles of ammonia combine with 1 mole of PAA to produce PAGN.
- Hepatic impairment had no significant effect on the ammonia-scavenging ability of HPN-100 in this study.
- the observations that hepatic impairment had no significant effect on the ammonia-scavenging ability of HPN-100 in this study but was associated with accumulation of PAA in plasma underscores the importance of utilizing urinary PAGN rather than metabolite blood levels to guide drug effect and, as a corollary, the importance of the invention.
- HPN-IOOc value is corrected for approximately 15% under collection of urine.
- PAGN was detectable in plasma samples of subjects receiving HPN-100 but not NaPBA after the 24 hour time point indicating that urinary collection of PAGN was incomplete at 24 hours following HPN-100 dosing.
- AUC 0 _ 24 Area under the concentration from time 0 (pre-dose) to 24 hours, Cmax ss : Maximum plasma concentration at steady state, Cmin ss : Minimum plasma concentration at steady state, A e : Amount excreted over 24 hours 1
- HPN-100 While the differences between sodium PBA and HPN-100 did not reach statistical significance due to the small sample size, HPN-100 exhibited a clear trend toward being more efficacious at equimolar dosages, and it was particularly effective for improving overnight control of ammonia levels.
- Figure 8a demonstrates that PBA levels in the blood are not correlated with HPN-100 dosages received. It plots the 24-hour AUC for PBA and the Cmax for PBA against HPN-100 dosage (top panel), and while the AUC and Cmax track together in each patient, they show no relationship to HPN-100 dose: both the highest and the lowest PBA exposures occurred in patients receiving high doses of HPN-100.
- Figure 8b shows that levels of PAA are similarly uncorrelated with HPN dosages.
- Figure 9 illustrates the trend shown in the clinical testing, where HPN-100 provided better overall control of waste nitrogen.
- Figure 10 illustrates that improved night time control of excess ammonia is achieved with HPN-100.
- FIG 11 shows that especially for patients with higher ammonia levels when treated with sodium PBA (Na PBA), HPN-100 provides better control than sodium PBA, while in patients with lower ammonia levels (ones for whom sodium PBA seems to work relatively well), HPN-100 provides at least comparable ammonia control. Note that for patients having ammonia levels above about 40 ⁇ mol/L when treated with sodium PBA, HPN-100 at equimolar dosages provided superior control of ammonia, and consistently reduced ammonia levels to below about 40 ⁇ mol/L. Thus for patients whose ammonia levels are abnormal (e.g.
- FIG. 12 illustrates that ammonia levels were better controlled in this test by HPN-100 than with sodium PBA, e.g., the average ammonia levels are lower, and tend to be below the upper limit for normal.
- Figure 13 shows a plot of Plasma Ammonia (TN-AUC) versus Urinary PAGN Excretion, and demonstrates the strong correlation between ammonia levels and urinary PAGN.
- TN-AUC Plasma Ammonia
- Example 2 a number of secondary statistical analyses comparing PK variables after fed versus fasted HPN-100 dosing and single versus multiple HPN-100 dosing were also done. There were no PK or PD differences observed when HPN-100 was administered after fasting (day 1) or with a meal (day 8). Accordingly, it is believed that HPN-100 can be effectively administered without the need for it to accompany a meal, while the label and package insert for sodium PBA (sodium PBA) indicate that it should be taken with meals.
- the table below also illustrates plasma accumulation of PAA that occurs with multiple dosing (Days 15 vs. 8).
- AUC 0 _ 12 area under the plasma concentration curve from time 0 up to 12 hours after dosing
- AUC 0 _ t area under the plasma concentration curve from time 0 to the last measurable concentration
- C 1111x maximum observed plasma concentration
- CV coefficient of variation
- geo. Mean, geometric mean
- n number of subjects
- SD standard deviation
- PBA is more slowly absorbed (-40% as fast) from the intestine after administration of HPN-100 versus sodium PBA (absorption rate constants and absorption half- lives for HPN- 100 and sodium PBA are 0.544 h "1 vs. 1.34 h "1 and 1.27 h vs. 0.52 h, respectively).
- corroborating the findings observed in humans (including the PK/PD modeling) and essentially no HPN-100 appeared in systemic circulation or in excretions.
- ammonia scavenging drugs of the types covered by this invention do not act on a target organ, rather they act through the combination of PAA with glutamine to form PAGN ( Figure 5).
- HPN-100 will be administered at a dose that is equivalent (equimolar) to an amount of sodium PBA that would be considered suitable for the particular patient; and the dosage can then be adjusted by the methods described herein.
- the HPN-100 dose range will match the PBA molar equivalent of the approved sodium PBA (sodium phenylbutyrate) (NaPBA) dose range.
- HPN-100 will be administered three times a day (TID) with meals. Note that the conversion of the dose of NaPBA to the dose of HPN-100 involves correction for their different chemical forms (i.e.
- HPN-100 is determined to be inadequate (e.g. patient requires an increase in dietary protein which would result in production of waste nitrogen exceeding his or her urea synthesis capacity and PAGN excretion), HPN-100 dose would be increased sufficiently to cover the necessary dietary protein and the same methodology of dose adjustment based on urinary PAGN excretion would be applied.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09748559A EP2338050A1 (en) | 2008-08-29 | 2009-08-27 | Dosing and monitoring patients on nitrogen-scavenging drugs |
JP2011525214A JP2012501451A (en) | 2008-08-29 | 2009-08-27 | Nitrogen scavenger administration and patient monitoring |
CA2735234A CA2735234A1 (en) | 2008-08-29 | 2009-08-27 | Dosing and monitoring patients on nitrogen-scavenging drugs |
US13/061,509 US20120022157A1 (en) | 2008-08-29 | 2009-08-27 | Dosing and monitoring patients on nitrogen-scavenging drugs |
GB0915545A GB2465250B (en) | 2008-08-29 | 2009-08-27 | Dosing and monitoring patients on nitrogen-scavenging drugs |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9323408P | 2008-08-29 | 2008-08-29 | |
US61/093,234 | 2008-08-29 | ||
USPCT/US09/30362 | 2009-01-07 | ||
PCT/US2009/030362 WO2009134460A1 (en) | 2008-04-29 | 2009-01-07 | Methods of treatment using ammonia-scavenging drugs |
US12/350,111 US8642012B2 (en) | 2008-04-29 | 2009-01-07 | Methods of treatment using ammonia-scavenging drugs |
US12/350,111 | 2009-01-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010025303A1 true WO2010025303A1 (en) | 2010-03-04 |
WO2010025303A9 WO2010025303A9 (en) | 2010-06-24 |
Family
ID=41203264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/055256 WO2010025303A1 (en) | 2008-08-29 | 2009-08-27 | Dosing and monitoring patients on nitrogen-scavenging drugs |
Country Status (5)
Country | Link |
---|---|
US (1) | US20120022157A1 (en) |
EP (1) | EP2338050A1 (en) |
CA (1) | CA2735234A1 (en) |
GB (1) | GB2465250B (en) |
WO (1) | WO2010025303A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2599482A1 (en) * | 2011-11-30 | 2013-06-05 | Lunamed AG | Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate) |
US8642012B2 (en) | 2008-04-29 | 2014-02-04 | Hyperion Therapeutics, Inc. | Methods of treatment using ammonia-scavenging drugs |
WO2014081977A1 (en) | 2012-11-21 | 2014-05-30 | Bruce Scharschmidt | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
US9095559B2 (en) | 2011-09-30 | 2015-08-04 | Horizon Therapeutics, Inc. | Methods of therapeutic monitoring of nitrogen scavenging drugs |
EP2846791A4 (en) * | 2012-04-20 | 2015-08-19 | Hyperion Therapeutics Inc | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
WO2019006164A1 (en) * | 2017-06-28 | 2019-01-03 | Baylor College Of Medicine | Combination therapy to treat urea cycle disorders |
WO2019051158A1 (en) * | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2986325T1 (en) * | 2013-10-14 | 2020-02-28 | Immedica Pharma Ab | Methods of treating urea cycle disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040229948A1 (en) * | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
ES2537974T3 (en) * | 2004-11-26 | 2015-06-16 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for the treatment of hepatic encephalopathy |
CA2711807A1 (en) * | 2008-01-08 | 2009-07-16 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
-
2009
- 2009-08-27 WO PCT/US2009/055256 patent/WO2010025303A1/en active Application Filing
- 2009-08-27 US US13/061,509 patent/US20120022157A1/en not_active Abandoned
- 2009-08-27 GB GB0915545A patent/GB2465250B/en active Active
- 2009-08-27 EP EP09748559A patent/EP2338050A1/en not_active Withdrawn
- 2009-08-27 CA CA2735234A patent/CA2735234A1/en not_active Withdrawn
Non-Patent Citations (4)
Title |
---|
LEE B ET AL: "Preliminary data on adult patients with urea cycle disorders (UCD) in an open-label, switch-over, dose-escalation study comparing a new ammonia scavenger, glyceryl tri(4-phenylbutyrate) (HPN-100), to buphenyl (sodium phenylbutyrate (PBA))", JOURNAL OF INHERITED METABOLIC DISEASE, KLUWER, DORDRECHT, NL, vol. 31, no. suppl. 1, 1 August 2008 (2008-08-01), pages 91, XP009127344, ISSN: 0141-8955 * |
MACARTHUR ROBERT B ET AL: "Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers", MOLECULAR GENETICS AND METABOLISM, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 81, no. Suppl.1, 1 April 2004 (2004-04-01), pages S67 - S73, XP009127291, ISSN: 1096-7192 * |
SIMELL O ET AL: "Waste nitrogen excretion via amino acid acylation: Benzoate and phenylacetate in lysinuric protein intolerance", PEDIATRIC RESEARCH, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 20, no. 11, 1 January 1986 (1986-01-01), pages 1117 - 1121, XP009127277, ISSN: 0031-3998 * |
TANNER L M ET AL: "Nutrient intake in lysinuric protein intolerance", JOURNAL OF INHERITED METABOLIC DISEASE, KLUWER ACADEMIC PUBLISHERS, DO, vol. 30, no. 5, 21 June 2007 (2007-06-21), pages 716 - 721, XP019548954, ISSN: 1573-2665 * |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8642012B2 (en) | 2008-04-29 | 2014-02-04 | Hyperion Therapeutics, Inc. | Methods of treatment using ammonia-scavenging drugs |
US9999608B2 (en) | 2011-09-30 | 2018-06-19 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
US10183005B2 (en) | 2011-09-30 | 2019-01-22 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
US10617665B2 (en) | 2011-09-30 | 2020-04-14 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
US10183002B2 (en) | 2011-09-30 | 2019-01-22 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
US10183006B2 (en) | 2011-09-30 | 2019-01-22 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
US9254278B2 (en) | 2011-09-30 | 2016-02-09 | Horizon Therapeutics, Inc. | Methods of therapeutic monitoring of nitrogen scavenging drugs |
US10183003B2 (en) | 2011-09-30 | 2019-01-22 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
US10045959B1 (en) | 2011-09-30 | 2018-08-14 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
US10183004B2 (en) | 2011-09-30 | 2019-01-22 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
US9962359B2 (en) | 2011-09-30 | 2018-05-08 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
US9326966B2 (en) | 2011-09-30 | 2016-05-03 | Horizon Therapeutics, Inc. | Methods of therapeutic monitoring of nitrogen scavenging drugs |
EP3263102A1 (en) | 2011-09-30 | 2018-01-03 | Horizon Therapeutics, LLC | Methods of therapeutic monitoring of nitrogen scavenging drugs |
US9095559B2 (en) | 2011-09-30 | 2015-08-04 | Horizon Therapeutics, Inc. | Methods of therapeutic monitoring of nitrogen scavenging drugs |
US10045958B1 (en) | 2011-09-30 | 2018-08-14 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
US9962358B2 (en) | 2011-09-30 | 2018-05-08 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
EP2599482A1 (en) * | 2011-11-30 | 2013-06-05 | Lunamed AG | Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate) |
WO2013079205A1 (en) * | 2011-11-30 | 2013-06-06 | Lunamed Ag | Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate) |
EP3222275A1 (en) | 2012-04-20 | 2017-09-27 | Horizon Therapeutics, LLC | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
US9561197B2 (en) | 2012-04-20 | 2017-02-07 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
EP2846791A4 (en) * | 2012-04-20 | 2015-08-19 | Hyperion Therapeutics Inc | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
EP3335735A1 (en) | 2012-11-21 | 2018-06-20 | Horizon Therapeutics, LLC | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
US9289406B2 (en) | 2012-11-21 | 2016-03-22 | Horizon Therapeutics, Inc. | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
AU2013347905B2 (en) * | 2012-11-21 | 2018-10-04 | Immedica Pharma Ab | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
EP2922576A4 (en) * | 2012-11-21 | 2016-05-04 | Horizon Therapeutics Inc | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
WO2014081977A1 (en) | 2012-11-21 | 2014-05-30 | Bruce Scharschmidt | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
US10329236B2 (en) | 2016-05-25 | 2019-06-25 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
US11014870B2 (en) | 2016-05-25 | 2021-05-25 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
US11819483B2 (en) | 2017-06-28 | 2023-11-21 | Baylor College Of Medicine | Combination therapy to treat urea cycle disorders |
US11517547B2 (en) | 2017-06-28 | 2022-12-06 | Baylor College Of Medicine | Combination therapy to treat urea cycle disorders |
WO2019006164A1 (en) * | 2017-06-28 | 2019-01-03 | Baylor College Of Medicine | Combination therapy to treat urea cycle disorders |
WO2019051158A1 (en) * | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
Also Published As
Publication number | Publication date |
---|---|
GB2465250B (en) | 2011-01-26 |
WO2010025303A9 (en) | 2010-06-24 |
GB0915545D0 (en) | 2009-10-07 |
EP2338050A1 (en) | 2011-06-29 |
US20120022157A1 (en) | 2012-01-26 |
GB2465250A (en) | 2010-05-19 |
CA2735234A1 (en) | 2010-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8642012B2 (en) | Methods of treatment using ammonia-scavenging drugs | |
US20120022157A1 (en) | Dosing and monitoring patients on nitrogen-scavenging drugs | |
AU2019201811B2 (en) | Methods of therapeutic monitoring of phenylacetic acid prodrugs | |
DK3133396T3 (en) | METHODS OF TREATMENT WHEN USING AMMONIA-CLEANING MEDICINES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 0915545 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20090827 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09748559 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2735234 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2011525214 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009748559 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13061509 Country of ref document: US |